Yes agree there will be some other costs (aside from dev capex) in addition to AISC. Last line should probably read cashflows before interest, principal repayts and other non-AISC costs. I would be surprised to see them cost an extra $500 an oz though? Interest expense of 60K for 2025 would add $90/oz.
I have spot sales at 3000 which is conservative/low (most spot sales in the last 12 months would be ~3080-3100).
Anyway this was just a rough out.
My point was just that if NPV discounted cashflows for only next 6 years are 341M, then the 88M of dev capex FY25-27 does not look unachievable, even if viewed through a lense where CAI has say 55-60M existing debt at the time of refinance say Dec24. Perhaps one would say a vanilla refinance if we were in a different environment for commodity project finance. There should also be large free cashflow in 26 & 27 whilst Blue Spec is being developed.
As we all know proof is in the pudding, lets see what next 2 qtrs brings. I'm shooting for 14K oz in March Q and 18K oz June Q. A June Q of 18K will give faith in the 66K 25FY guidance.
- Forums
- ASX - By Stock
- Ann: Production and cashflow guidance increases
Yes agree there will be some other costs (aside from dev capex)...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CAI (ASX) to my watchlist
(20min delay)
|
|||||
Last
12.0¢ |
Change
-0.005(4.00%) |
Mkt cap ! $91.36M |
Open | High | Low | Value | Volume |
12.5¢ | 13.0¢ | 12.0¢ | $114.2K | 911.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 1180827 | 12.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.5¢ | 83790 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 1180827 | 0.120 |
21 | 2142655 | 0.115 |
10 | 962900 | 0.110 |
8 | 969997 | 0.105 |
10 | 796301 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 83790 | 1 |
0.130 | 325236 | 6 |
0.135 | 608872 | 7 |
0.140 | 781945 | 14 |
0.145 | 341750 | 4 |
Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
12.0¢ |
  |
Change
-0.005 ( 5.88 %) |
|||
Open | High | Low | Volume | ||
12.8¢ | 12.8¢ | 12.0¢ | 451652 | ||
Last updated 15.21pm 06/05/2024 ? |
Featured News
CAI (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online